• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钙激活钾通道 K1.1 作为克服三维肉瘤球体模型中化疗耐药性的治疗靶点。

Ca -activated K channel K 1.1 as a therapeutic target to overcome chemoresistance in three-dimensional sarcoma spheroid models.

机构信息

Department of Pharmacology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.

Department of Complex Molecular Chemistry, The Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan.

出版信息

Cancer Sci. 2021 Sep;112(9):3769-3783. doi: 10.1111/cas.15046. Epub 2021 Jul 16.

DOI:10.1111/cas.15046
PMID:34181803
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8409426/
Abstract

The large-conductance Ca -activated K channel K 1.1 plays a pivotal role in tumor development and progression in several solid cancers. The three-dimensional (3D) in vitro cell culture system is a powerful tool for cancer spheroid formation, and mimics in vivo solid tumor resistance to chemotherapy in the tumor microenvironment (TME). K 1.1 is functionally expressed in osteosarcoma and chondrosarcoma cell lines. K 1.1 activator-induced hyperpolarizing responses were significantly larger in human osteosarcoma MG-63 cells isolated from 3D spheroid models compared with in those from adherent 2D monolayer cells. The present study investigated the mechanisms underlying the upregulation of K 1.1 and its role in chemoresistance using a 3D spheroid model. K 1.1 protein expression levels were significantly elevated in the lipid-raft-enriched compartments of MG-63 spheroids without changes in its transcriptional level. 3D spheroid formation downregulated the expression of the ubiquitin E3 ligase FBXW7, which is an essential contributor to K 1.1 protein degradation in breast cancer. The siRNA-mediated inhibition of FBXW7 in MG-63 cells from 2D monolayers upregulated K 1.1 protein expression. Furthermore, a treatment with a potent and selective K 1.1 inhibitor overcame the chemoresistance of the MG-63 and human chondrosarcoma SW-1353 spheroid models to paclitaxel, doxorubicin, and cisplatin. Among several multidrug resistance ATP-binding cassette transporters, the expression of the multidrug resistance-associated protein MRP1 was upregulated in both spheroids and restored by the inhibition of K 1.1. Therefore, the pharmacological inhibition of K 1.1 may be an attractive new strategy for acquiring resistance to chemotherapeutic drugs in the TME of K 1.1-positive sarcomas.

摘要

大电导钙激活钾通道 K 1.1 在几种实体瘤的肿瘤发生和进展中发挥关键作用。三维(3D)体外细胞培养系统是形成肿瘤球体的有力工具,可模拟肿瘤微环境(TME)中体内实体肿瘤对化疗的耐药性。K 1.1 在骨肉瘤和软骨肉瘤细胞系中功能性表达。与来自贴壁 2D 单层细胞的细胞相比,从 3D 球体模型分离的人骨肉瘤 MG-63 细胞中 K 1.1 激活剂诱导的超极化反应明显更大。本研究使用 3D 球体模型研究了 K 1.1 上调的机制及其在化疗耐药中的作用。K 1.1 蛋白表达水平在 MG-63 球体富含脂筏的隔室中显著升高,而其转录水平没有变化。3D 球体形成下调了泛素 E3 连接酶 FBXW7 的表达,FBXW7 是乳腺癌中 K 1.1 蛋白降解的重要贡献者。在来自 2D 单层的 MG-63 细胞中用 siRNA 抑制 FBXW7 可上调 K 1.1 蛋白表达。此外,用一种有效的、选择性的 K 1.1 抑制剂处理可克服 MG-63 和人软骨肉瘤 SW-1353 球体模型对紫杉醇、多柔比星和顺铂的化疗耐药性。在几种多药耐药 ATP 结合盒转运蛋白中,多药耐药相关蛋白 MRP1 的表达在球体中均上调,并通过抑制 K 1.1 恢复。因此,药理学抑制 K 1.1 可能是一种有吸引力的新策略,可用于获得 K 1.1 阳性肉瘤 TME 中化疗药物的耐药性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/5938c9c40321/CAS-112-3769-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/074fe00336ac/CAS-112-3769-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/9d21a61e4785/CAS-112-3769-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/9ef5a21053c9/CAS-112-3769-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/361b7a51b51b/CAS-112-3769-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/43c52e4a64c3/CAS-112-3769-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/7ef34207318c/CAS-112-3769-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/aed9a470b534/CAS-112-3769-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/6a6e2dc33dc8/CAS-112-3769-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/5817eee0c0e2/CAS-112-3769-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/acbadf7080d6/CAS-112-3769-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/5938c9c40321/CAS-112-3769-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/074fe00336ac/CAS-112-3769-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/9d21a61e4785/CAS-112-3769-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/9ef5a21053c9/CAS-112-3769-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/361b7a51b51b/CAS-112-3769-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/43c52e4a64c3/CAS-112-3769-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/7ef34207318c/CAS-112-3769-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/aed9a470b534/CAS-112-3769-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/6a6e2dc33dc8/CAS-112-3769-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/5817eee0c0e2/CAS-112-3769-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/acbadf7080d6/CAS-112-3769-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6d6/8409426/5938c9c40321/CAS-112-3769-g009.jpg

相似文献

1
Ca -activated K channel K 1.1 as a therapeutic target to overcome chemoresistance in three-dimensional sarcoma spheroid models.钙激活钾通道 K1.1 作为克服三维肉瘤球体模型中化疗耐药性的治疗靶点。
Cancer Sci. 2021 Sep;112(9):3769-3783. doi: 10.1111/cas.15046. Epub 2021 Jul 16.
2
Transcriptional Up-Regulation of FBXW7 by K1.1 K Channel Inhibition through the Nrf2 Signaling Pathway in Human Prostate Cancer LNCaP Cell Spheroid Model.通过 Nrf2 信号通路抑制 K1.1 K 通道对人前列腺癌细胞球体模型 FBXW7 的转录上调。
Int J Mol Sci. 2024 May 30;25(11):6019. doi: 10.3390/ijms25116019.
3
K1.1 K Channel Inhibition Overcomes Resistance to Antiandrogens and Doxorubicin in a Human Prostate Cancer LNCaP Spheroid Model.K1.1 钾通道抑制克服了人前列腺癌 LNCaP 球体模型中对雄激素拮抗剂和多柔比星的耐药性。
Int J Mol Sci. 2021 Dec 17;22(24):13553. doi: 10.3390/ijms222413553.
4
Down-Regulation of CYP3A4 by the K1.1 Inhibition Is Responsible for Overcoming Resistance to Doxorubicin in Cancer Spheroid Models.K1.1 抑制下调 CYP3A4 负责克服癌症球体模型中对多柔比星的耐药性。
Int J Mol Sci. 2023 Oct 27;24(21):15672. doi: 10.3390/ijms242115672.
5
Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.蛋白组学方法研究球体培养系统中骨肉瘤细胞耐药的分子背景。
Proteomics. 2013 Aug;13(15):2351-60. doi: 10.1002/pmic.201300053. Epub 2013 Jun 28.
6
[Overcoming chemoresistance by Ca-activated K channel inhibition in cancer spheroid models].[在癌症球体模型中通过抑制钙激活钾通道克服化学抗性]
Nihon Yakurigaku Zasshi. 2023;158(6):478-482. doi: 10.1254/fpj.23039.
7
Blocking miR-27a-3p sensitises Taxol resistant osteosarcoma cells through targeting Fbxw7.阻断 miR-27a-3p 通过靶向 Fbxw7 增敏紫杉醇耐药骨肉瘤细胞。
Bull Cancer. 2021 Jun;108(6):596-604. doi: 10.1016/j.bulcan.2021.01.006. Epub 2021 Apr 15.
8
Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.结直肠癌干细胞通过上调含F-Box/WD重复序列蛋白7并随后降解c-Myc获得化疗耐药性。
Stem Cells. 2017 Sep;35(9):2027-2036. doi: 10.1002/stem.2668. Epub 2017 Jul 31.
9
PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.PAXX 是克服骨肉瘤对阿霉素和顺铂耐药的一个新靶点。
Biochem Biophys Res Commun. 2020 Jan 1;521(1):204-211. doi: 10.1016/j.bbrc.2019.10.108. Epub 2019 Oct 19.
10
Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells.丙磺舒对前列腺癌细胞三维培养的多效作用。
Life Sci. 2021 Aug 1;278:119554. doi: 10.1016/j.lfs.2021.119554. Epub 2021 Apr 28.

引用本文的文献

1
Ubiquitination in lipid metabolism reprogramming: implications for pediatric solid tumors.脂质代谢重编程中的泛素化:对小儿实体瘤的影响
Front Immunol. 2025 Apr 30;16:1554311. doi: 10.3389/fimmu.2025.1554311. eCollection 2025.
2
Developing a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatments.构建骨肉瘤的三维骨骼模型以研究癌症机制并评估治疗方法。
FASEB J. 2024 Dec 13;38(24):e70274. doi: 10.1096/fj.202402011R.
3
Transcriptional regulation of KCNA2 coding Kv1.2 by EWS::FLI1: involvement in controlling the YAP/Hippo signalling pathway and cell proliferation.

本文引用的文献

1
Decreased expression of FBXW7 by ERK1/2 activation in drug-resistant cancer cells confers transcriptional activation of MDR1 by suppression of ubiquitin degradation of HSF1.ERK1/2 激活导致耐药癌细胞中 FBXW7 表达降低,通过抑制 HSF1 泛素降解来赋予 MDR1 转录激活。
Cell Death Dis. 2020 May 26;11(5):395. doi: 10.1038/s41419-020-2600-3.
2
F-Box Proteins and Cancer.F盒蛋白与癌症
Cancers (Basel). 2020 May 15;12(5):1249. doi: 10.3390/cancers12051249.
3
High-throughput screening in multicellular spheroids for target discovery in the tumor microenvironment.
EWS::FLI1对编码Kv1.2的KCNA2的转录调控:参与控制YAP/河马信号通路和细胞增殖。
Cell Commun Signal. 2024 Dec 18;22(1):602. doi: 10.1186/s12964-024-01981-4.
4
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions.组织工程化患者来源骨肉瘤模型解析肿瘤-骨相互作用。
Cancer Metastasis Rev. 2024 Nov 27;44(1):8. doi: 10.1007/s10555-024-10218-2.
5
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies.泛素化在骨肉瘤中的作用:揭示其对细胞生物学和治疗策略的影响。
Cancer Biol Med. 2024 Oct 30;21(10):880-97. doi: 10.20892/j.issn.2095-3941.2024.0231.
6
Transcriptional Up-Regulation of FBXW7 by K1.1 K Channel Inhibition through the Nrf2 Signaling Pathway in Human Prostate Cancer LNCaP Cell Spheroid Model.通过 Nrf2 信号通路抑制 K1.1 K 通道对人前列腺癌细胞球体模型 FBXW7 的转录上调。
Int J Mol Sci. 2024 May 30;25(11):6019. doi: 10.3390/ijms25116019.
7
3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine.肉瘤的3D模型:个性化医疗的下一代工具。
Phenomics. 2023 Oct 4;4(2):171-186. doi: 10.1007/s43657-023-00111-3. eCollection 2024 Apr.
8
Enhanced Biomimetics of Three-Dimensional Osteosarcoma Models: A Scoping Review.三维骨肉瘤模型的增强仿生学:一项范围综述
Cancers (Basel). 2023 Dec 28;16(1):164. doi: 10.3390/cancers16010164.
9
Down-Regulation of CYP3A4 by the K1.1 Inhibition Is Responsible for Overcoming Resistance to Doxorubicin in Cancer Spheroid Models.K1.1 抑制下调 CYP3A4 负责克服癌症球体模型中对多柔比星的耐药性。
Int J Mol Sci. 2023 Oct 27;24(21):15672. doi: 10.3390/ijms242115672.
10
Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine.骨肉瘤模型在药物发现和精准医学中的研究进展
Biomolecules. 2023 Sep 7;13(9):1362. doi: 10.3390/biom13091362.
用于肿瘤微环境中靶点发现的多细胞球体高通量筛选
Expert Opin Drug Discov. 2020 Aug;15(8):955-967. doi: 10.1080/17460441.2020.1756769. Epub 2020 May 4.
4
SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop.SIRT1 通过启动 AMPK/FOXO3 正反馈环抑制胃癌的化疗耐药性和癌症干性。
Cell Death Dis. 2020 Feb 12;11(2):115. doi: 10.1038/s41419-020-2308-4.
5
Roles for Ca and K channels in cancer cells exposed to the hypoxic tumour microenvironment.钙和钾通道在缺氧肿瘤微环境中暴露的癌细胞中的作用。
Biochim Biophys Acta Mol Cell Res. 2020 Apr;1867(4):118644. doi: 10.1016/j.bbamcr.2020.118644. Epub 2020 Jan 10.
6
Allyl isothiocyanate treatment alleviates chronic obstructive pulmonary disease through the Nrf2-Notch1 signaling and upregulation of MRP1.丙烯基异硫氰酸酯通过 Nrf2-Notch1 信号通路和上调 MRP1 缓解慢性阻塞性肺疾病。
Life Sci. 2020 Feb 15;243:117291. doi: 10.1016/j.lfs.2020.117291. Epub 2020 Jan 9.
7
High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment.高 Notch1 表达影响头颈部鳞状细胞癌对紫杉醇和顺铂治疗的化疗敏感性。
Biomed Pharmacother. 2019 Oct;118:109306. doi: 10.1016/j.biopha.2019.109306. Epub 2019 Aug 13.
8
Contribution of Mitochondrial Ion Channels to Chemo-Resistance in Cancer Cells.线粒体离子通道对癌细胞化疗耐药性的作用
Cancers (Basel). 2019 May 31;11(6):761. doi: 10.3390/cancers11060761.
9
Ion Channels: New Actors Playing in Chemotherapeutic Resistance.离子通道:化疗耐药中发挥作用的新角色。
Cancers (Basel). 2019 Mar 16;11(3):376. doi: 10.3390/cancers11030376.
10
FBXW7 in Cancer: What Has Been Unraveled Thus Far?癌症中的FBXW7:迄今为止已揭示了什么?
Cancers (Basel). 2019 Feb 19;11(2):246. doi: 10.3390/cancers11020246.